Weight & Metabolism
GLP-1 drugs, next-generation incretins and research peptides for fat loss and metabolic health.
-
Orforglipron vs Zepbound: differences, evidence and safety
Orforglipron (Foundayo) is a once-daily GLP-1 pill, FDA-approved for weight management on April 1, 2026. Zepbound (tirzepatide) is a once-weekly GIP/GLP-1 injection approved in…
-
Tesamorelin vs CJC-1295 + Ipamorelin for Fat Loss: Differences, Evidence and Safety
Tesamorelin is an FDA-approved drug (Egrifta) with phase 3 trials showing it shrinks deep belly fat in people with HIV-associated lipodystrophy; CJC-1295 and ipamorelin…
-
CagriSema vs Zepbound: differences, evidence and safety
CagriSema is an investigational once-weekly injection that combines cagrilintide (an amylin analogue) with semaglutide. Novo Nordisk filed it with the FDA in December 2025…
-
Retatrutide and cagrilintide: what is known about the combination
Retatrutide and cagrilintide are two investigational weight-loss drugs that have never been tested together in people. Retatrutide (Eli Lilly) acts on three gut-hormone receptors…
-
Survodutide vs Retatrutide: differences, evidence and safety
Survodutide is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim; retatrutide is a GIP/GLP-1/glucagon triple agonist from Eli Lilly. Neither is FDA approved. Both now…
-
Retatrutide vs CagriSema: which comes first? Trials, FDA timeline and safety
Verdict: Retatrutide has the larger trial weight loss, 25.0% at 80 weeks [Human RCT, n=2,339]. CagriSema produced 20.4% at 68 weeks [Human RCT, n=3,417]…
-
Retatrutide vs Tirzepatide vs Semaglutide: differences, evidence and safety
Retatrutide vs tirzepatide vs semaglutide, in short: semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are FDA-approved drugs backed by large phase 3 trials, and…